CompletedPHASE2, PHASE3NCT04692766
Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis
Studying Idiopathic recurrent pericarditis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- R-Pharm International, LLC
- Principal Investigator
- Mikhail SamsonovR-Pharm
- Intervention
- RPH-104(biological)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (2)
- Federal Budgetary Healthcare Institution Orenburg Regional Clinical Hospital, Orenburg, Russia
- Federal State Budget Institution "V.A. Almazov National Medical Research Center" of Ministry of Healthcare of Russian Federation, Saint Petersburg, Russia
Collaborators
Unimed Laboratories · Data Management 365 · Center of Pharmaceutical Analytics LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04692766 on ClinicalTrials.govOther trials for Idiopathic recurrent pericarditis
Additional recruiting or active studies for the same condition.